Please login to the form below

Not currently logged in
Email:
Password:

mutiple myeloma

This page shows the latest mutiple myeloma news and features for those working in and with pharma, biotech and healthcare.

Mixed cancer news from NICE

Mixed cancer news from NICE

Agency backs Janssen’s myeloma drug but denies Bayer’s Xofigo in prostate cancer. ... The cost-effectiveness agency issued draft guidance giving the green light to Janssen's Velcade in the treatment of certain patients with multiple myeloma in

Latest news

  • NICE denies early use of Janssen’s Velcade NICE denies early use of Janssen’s Velcade

    Draft guidance doesn't recommend expanded bone marrow cancer indication. Janssen's Velcade is not a cost-effective use of NHS resources for the early treatment of multiple myeloma, according to ... The drug is already recommended by NICE for use in

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

DNA
Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...

Infographics